Post IMS 2024 : actualités en 1ère ligne chez les patients non éligibles à la greffe

Dr Arthur Bobin

CHU de Poitiers - Hôpital la Milétrie
Pôle Régional de Cancérologie
Poitiers, France

Mercredi 16 octobre 2024 – Paris

N=446

IMROZ: IsaVRd vs VRd





M. Dimopoulos, presented at IMS 2024

IMROZ: IsaVRd vs VRd

PFS





MRD



Preferred term, n (%)	Isa-VRd (n=263)		VRd (n=181)	
	Any grade	Grade ≥3	Any grade	Grade ≥3
Infections	240 (91.3)	118 (44.9)	157 (86.7)	69 (38.1)
Pneumonia	79 (30.0)	53 (20.2)	35 (19.3)	23 (12.7)
Upper respiratory tract infection	90 (34.2)	2 (0.8)	61 (33.7)	2 (1.1)
Peripheral sensory neuropathy	143 (54.4)	19 (7.2)	110 (60.8)	11 (6.1)

M. Dimopoulos, presented at IMS 2024

BENEFIT: IsaVRd vs IsaRd

N=135 each group
Median age: 73.2 and 73.6 yo ; ≥75: 31 and 36%
R ISS 3: 8% each
HR : 8 and 10%



X Leleu, presented at IMS 2024

BENEFIT: IsaVRd vs IsaRd

MRD



Estimated 24 months PFS:

85.2% for Isa-VRd

80.0% for Isa-Rd

PFS



Event, no. of patients (%)	Isa-VRd (n=135)		Isa-Rd (n=135)	
	Any Grade	≥Grade 2	Any Grade	≥Grade 2
Nonhematologic adverse events (cont'd)				
Eye disorders	20 (15)	10 (7)	19 (14)	12 (8)
SPMs	6 (4)	6 (4)	6 (4)	6 (4)
Infections and infestations				
Infection of other types	61 (45)	48 (36)	48 (36)	35 (28)
Infection of the respiratory system	65 (48)	47 (35)	64 (47)	54 (40)
Covid-19	55 (41)	34 (24)	59 (44)	31 (23)
Nervous system disorders				
Peripheral neuropathy	70 (52)	37 (27)†	38 (28)	13 (10)‡
Other	38 (28)	19 (14)	41 (30)	17 (13)

X Leleu, presented at IMS2024

CEPHEUS: DVRd vs VRd

N=197 et 198
Median age: 70
Transplant ineligible 73% ; transplant deferred 27%
HR 13%



S Usmani, presented at IMS 2024

CEPHEUS: DVRd vs VRd

N=197 et 198
Median age: 70
Transplant ineligible 73% ; transplant deferred 27%
HR 13%

MRD

Primary endpoint
Overall MRD-negativity rate (10^{-5})



Overall MRD-negativity rate (10^{-6})



Durée médiane du traitement : **56.3 mois** **vs** 34.3 mois
Taux de ≥CR **81.2%** avec **DVRd** **vs** 61.6% pour VRd
Sustained MRD negative ≥12 mois = **48.7%** **vs** 26.3%

S Usmani, presented at IMS 2024

CEPHEUS: DVRd vs VRd

N=197 et 198
Median age: 70
Transplant ineligible 73% ; transplant deferred 27%
HR 13%

PFS



OS



AE

	Any grade	Grade 2	Grade 3 or 4	Any grade	Grade 2	Grade 3 or 4
Peripheral sensory neuropathy	110 (55.8)	60 (30.5)	16 (8.1)	119 (61.0)	70 (35.9)	16 (8.2)

Any grade 3 or 4 TEAE: **92.4** vs **85.6%**
TEAE leading to discontinuation: **7.6%** vs **15.9%**

S Usmani, presented at IMS 2024

CC-220-MM-001: Iber + Dara + dex

N=75
Median age: 75 yo ; 59% de ≥75 yo
HR: 41.3%
R ISS 3 18.7%

Phase 1: dose escalation

- Cohort A: IBER
- Cohort B: IBER + DEX
- Cohort E: IBER + DARA + DEX
- Cohort F: IBER + BORT + DEX
- Cohort G: IBER + CFZ + DEX

Phase 2: dose expansion[a]

- Cohort D: IBER[b] + DEX
- Cohort I (post BCMA): IBER[b] + DEX
- Cohort J1 (NDMM TNE): IBER + BORT + DEX
- **Cohort K (NDMM TNE): IBER + DARA + DEX**

Key eligibility criteria

- Adults (≥ 18 years of age) with NDMM
- Previously untreated symptomatic MM[a]
- No ASCT planned for initial therapy or ASCT ineligible[b]
- Measurable disease

Treatments[c]

- n = 25: IBER[d] (1.0 mg) + DARA[e] + DEX[f], 28-day cycles
- n = 25: IBER[d] (1.3 mg) + DARA[e] + DEX[f], 28-day cycles
- n = 25: IBER[d] (1.6 mg) + DARA[e] + DEX[f], 28-day cycles

IBER: D1-21 of each cycle
DARA: 1800 mg SC, QW C1-2, Q2W C3-6, Q4W C ≥ 7
DEX: 40 mg (20 mg if > 75 years of age) QW

Objectives

- Evaluation of the preliminary efficacy and safety of IberDd in NDMM-TNE
- PK assessment, MRD evaluation, biomarkers
- MRD evaluation during treatment for patients with ≥ VGPR



Sureda, presented at IMS 2024

CC-220-MM-001: Iber + Dara + dex

N=75
Median age: 75 yo ; 59% de ≥75 yo
HR: 41.3%
R ISS 3 18.7%



MRD

MRD negativity rates[c] evaluated in patients with ≥ VGPR

	Efficacy-evaluable population (N = 73)	Patients with ≥ VGPR (N = 65)
MRD negativity rate,[c] n (%)	28 (38.4)	28 (43.1)

FUP median: 13.9 mois
Au cutoff, 83% des patients toujours sous traitement
durée médiane du traitement = 13.5 mois
En médiane, 14 cycles reçus

Sureda, presented at IMS 2024

CC-220-MM-001: Iber + Dara + dex

N=75
Median age: 75 yo ; 59% de ≥75 yo
HR: 41.3%
R ISS 3 18.7%

AE

Most common (≥ 25% all grade) TEAEs and events of interest,[a] n (%)	IberDd TNE NDMM (N = 75)		
	All grade	Grade 3	Grade 4
Any TEAE	75 (100)	35 (46.7)	36 (48.0)
Hematologic TEAEs			
Neutropenia	60 (80.0)	26 (34.7)	30 (40.0)
Febrile neutropenia	9 (12.0)	9 (12.0)	0
Anemia	25 (33.3)	8 (10.7)	0
Lymphopenia	24 (32.0)	10 (13.3)	5 (6.7)
Leukopenia	17 (22.7)	8 (10.7)	3 (4.0)
Thrombocytopenia	16 (21.3)	2 (2.7)	1 (1.3)
Non-hematologic TEAEs			
Constipation	26 (34.7)	0	0
Rash[b]	24 (32.0)	2 (2.7)	0
Fatigue	20 (26.7)	1 (1.3)	0
Pyrexia	20 (26.7)	2 (2.7)	0
Peripheral edema	20 (26.7)	0	0
Nausea	19 (25.3)	2 (2.7)	0
Diarrhea	17 (22.7)	0	0
Infections	63 (84.0)	26 (34.7)	3 (4.0)
COVID-19[c]	24 (32.0)	4 (5.3)	0
Pneumonia[d]	19 (25.3)	17 (22.7)	2 (2.7)



Neutropénies plus fréquentes les 2 premiers cycles, puis diminution

Sureda, presented at IMS 2024